MEK Inhibitors Targeting ERK Pathway Specificity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments using protein kinase inhibitors often have side effects due to lack of specificity, and there is a need for more effective targeting of the MEK-ERK signal transduction pathway, which is aberrantly activated in many human tumors.
Innovation Solution
Development of azetidin-1-yl(2-(2-fluorophenylamino)cyclic)methanones derivatives that inhibit MEK kinase activity, providing a compound useful in treating hyperproliferative diseases like cancer by modulating the MEK-ERK pathway.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional protein kinase inhibitors are used to treat cancer, then cancer treatment efficacy is achieved, but side effects increase due to lack of specificity
Solution Approach 1:
The patent applies local quality by designing MEK-specific inhibitors with unique molecular structures (Formula I compounds with specific substituents R1-R7) that target only the MEK kinase domain, leaving other protein kinases unaffected. This selective targeting achieves cancer treatment efficacy while minimizing side effects by concentrating the inhibitory action at the specific MEK site rather than broadly inhibiting all protein kinases.
Solution Approach 2:
The patent employs parameter changes by systematically varying molecular parameters of the inhibitor compounds through different substituents (R1-R7 groups) to optimize binding affinity and specificity for MEK. By adjusting these molecular parameters, the inhibitors achieve high efficacy against MEK while maintaining selectivity that reduces harmful side effects on other cellular processes.
2Reliability
If MEK-ERK pathway is targeted for inhibition, then anti-metastatic and anti-angiogenic effects are achieved, but the complexity of the signaling pathway makes selective inhibition difficult
Solution Approach 1:
The patent applies the extraction principle by isolating and targeting the MEK component within the MEK-ERK signaling pathway, separating its inhibition from the rest of the complex pathway. By focusing the inhibitor design specifically on MEK's catalytic domain, the patent achieves anti-metastatic and anti-angiogenic effects without needing to address the entire complex signaling network, thereby simplifying the therapeutic approach.
Solution Approach 2:
The patent uses segmentation by dividing the MEK-ERK pathway into distinct functional components and targeting only the MEK segment with specific inhibitors. This segmentation allows selective inhibition of MEK kinase activity while leaving ERK and other pathway components unaffected, managing the complexity of the overall signaling pathway through focused intervention.
3Productivity
If broad-spectrum protein kinase inhibitors are used, then multiple kinase activities are suppressed, but therapeutic specificity decreases and side effects increase
Solution Approach 1:
The patent applies local quality by designing inhibitors with specific molecular features (Formula I structure with defined R1-R7 substituents) that confer selective binding to MEK. This localized specificity allows the inhibitors to suppress MEK activity effectively while avoiding off-target effects on other kinases, thereby maintaining high therapeutic specificity even with focused kinase inhibition coverage.
Solution Approach 2:
The patent employs parameter changes by optimizing the molecular parameters of the inhibitor compounds through systematic variation of substituents. This optimization enhances the binding affinity and specificity for MEK, allowing the inhibitors to achieve effective kinase inhibition coverage for MEK while maintaining high therapeutic specificity and avoiding broad-spectrum side effects.
Data Source
AI summary
Disclosed am compounds of Formula (I) and pharmaceutically acceptable salts and solvates thereof. Such compounds are MEK inhibitors and am useful in the treatment of proliferative diseases, such as cancer. Also disclosed are pharmaceutical compositions containing such compounds as well as methods of using the compounds and compositions of the invention in the treatment of cancer.